★ Royal November Sale 20% off sitewide Ends in   Shop the sale →
Every Batch 3rd Party HPLC TestedFree shipping over $300 · USA domesticOrder by 2pm EST- ships same business dayYou are on the official Royal Peptides website — verify the link3rd-party verified COAs · Same-day shipping
✓ Verify official site
My account
SLU-PP-332 20mg 50 Capsules
Research use only Laboratory research materials

Royal Peptides products are offered exclusively for laboratory research, analytical and scientific applications. Not for human or veterinary use.

01Research product information

Royal Peptides supplies compounds intended for controlled laboratory research and analytical applications.

  • For research and analytical use only
  • Not intended for human consumption or administration
  • Not intended for veterinary use
  • Not represented as a drug, medicine or therapeutic product
  • Laboratory researchers are responsible for appropriate protocols and controls

Research onlyLaboratory materialAnalytical use

02Lyophilized product format

Where applicable, Royal Peptides research materials are supplied in lyophilized form. Lyophilization is a freeze-drying process used to remove moisture from material under controlled conditions.

  • Material appearance may differ between compounds and production lots
  • Lyophilized material may appear as a cake, film or fragmented material
  • The quantity of visible material may appear small relative to vial size
  • Visual appearance alone does not establish identity or purity
03Storage & laboratory handling

Storage requirements may vary by compound, formulation and production lot. Refer to the product label and available product-specific documentation.

  • Protect research materials from excessive heat
  • Limit unnecessary exposure to direct light and moisture
  • Keep containers securely closed when stored
  • Follow product-specific temperature requirements when provided
  • Use appropriate laboratory contamination-control procedures
04Packaging & quality documentation

Packaging components may vary slightly between production lots. This can include vial closures, cap styles, label positioning and external packaging.

  • Check the product label and lot identifier before laboratory use
  • Inspect the vial and closure for visible shipping damage
  • Packaging design may differ between batches
  • Lot-specific analytical documentation may be available in our COA library

View COA library →

Oral Research In stock

SLU-PP-332

Price range: $140.00 through $285.00
$28.50/mg
Buy more · save morePick a bundle
Lowest price 10vial kit Shop kits View →
  

Please review before orderingImportant product notice
10-vial kits — vials are not individually labeled
10-vial research kits are supplied without individual vial labels. Product and batch identification are provided with the kit packaging.
Reconstitution materials
For reconstitution-related research, use Royal Peptides® Reconstitution Solution ↗ or a genuine manufacturer-sealed Hospira® / Pfizer® product where applicable.
Support notice
Support may be limited when unverified third-party materials are used.
Third-party testedBatch COA on file
Same-day shippingOn in-stock orders
Discreet & securePlain packaging

Research noticeFor laboratory and research purposes only. Not intended for human consumption, diagnostic or therapeutic use, or administration to humans or animals.

Research Compound • 2026 Reference

SLU-PP-332 Research Compound

SLU-PP-332 is an experimental synthetic small-molecule pan-estrogen-related receptor agonist studied for activity across ERRα, ERRβ and ERRγ and for its role in preclinical research involving mitochondrial biology, oxidative metabolism, skeletal-muscle signaling and exercise-associated pathways.

Pan-ERR Agonist ERRα / ERRβ / ERRγ Small Molecule Mitochondrial Research Preclinical Research Research Use Only
Compound Class Synthetic Small Molecule
Research Targets ERRα / ERRβ / ERRγ
Pharmacology Pan-ERR Agonist
Research Status Preclinical

What Is SLU-PP-332?

SLU-PP-332 is a synthetic research compound developed as a pharmacological agonist of the estrogen-related receptor family of nuclear receptors.

Published experimental work characterizes SLU-PP-332 as active across ERRα, ERRβ and ERRγ, with greater potency toward ERRα reported in its original characterization.

Despite sometimes being grouped with peptide research products, SLU-PP-332 is not a peptide. It is a synthetic small molecule used experimentally to investigate pharmacological activation of estrogen-related receptor signaling.

How Does SLU-PP-332 Work in Research Models?

Estrogen-related receptors are transcriptional regulators associated with cellular energy metabolism. Experimental activation of these receptors provides researchers with a method for investigating ERR-dependent metabolic and mitochondrial pathways.

SLU-PP-332
ERRα / ERRβ / ERRγ
Transcriptional Signaling
Metabolic & Mitochondrial Research

ERR signaling has been associated with biological processes including oxidative phosphorylation, fatty-acid metabolism, mitochondrial function and energy utilization in metabolically active tissues.

SLU-PP-332 Research Areas

Published preclinical research has made SLU-PP-332 a useful experimental tool across several areas of metabolic and mitochondrial biology.

01

ERR Signaling

Investigation of pharmacological activation across the ERRα, ERRβ and ERRγ nuclear-receptor family.

02

Mitochondrial Biology

Research involving mitochondrial function, cellular respiration and pathways associated with oxidative energy metabolism.

03

Skeletal-Muscle Research

Experimental investigation of oxidative skeletal-muscle characteristics and exercise-associated transcriptional responses.

04

Energy Metabolism

Research involving fatty-acid oxidation, cellular energy utilization and ERR-regulated metabolic pathways.

SLU-PP-332 and PGC-1α

SLU-PP-332 is sometimes described online as a “PGC-1α activator.” That description can obscure its experimentally characterized primary pharmacology.

SLU-PP-332 is more precisely described as a synthetic pan-ERR agonist. PGC-1 family coactivators participate in broader transcriptional networks relevant to ERR signaling and mitochondrial energy metabolism.

i

Research classification: ERRα, ERRβ and ERRγ are the pharmacological receptor targets used to characterize SLU-PP-332. PGC-1α is relevant to the surrounding transcriptional biology rather than being presented as the compound's direct primary target.

SLU-PP-332 and Mitochondrial Research

The connection between estrogen-related receptors and cellular energy regulation is one reason SLU-PP-332 has attracted substantial research interest.

ERR-regulated transcription participates in pathways associated with mitochondrial function, oxidative phosphorylation, fatty-acid oxidation and cellular energy metabolism.

Synthetic ERR agonists therefore provide experimental tools for studying how pharmacological activation of these transcriptional networks affects metabolic and mitochondrial biology in preclinical models.

Why Is SLU-PP-332 Studied as an Exercise Mimetic?

SLU-PP-332 has received considerable research attention because preclinical studies have examined whether pharmacological ERR activation can reproduce selected molecular and metabolic responses associated with aerobic exercise.

This has led to SLU-PP-332 being discussed within the experimental “exercise mimetic” field.

!

Important distinction: “Exercise mimetic” is a research concept. It does not establish that SLU-PP-332 reproduces the broad cardiovascular, neurological, musculoskeletal and metabolic effects of physical exercise in humans.

Is SLU-PP-332 Orally Bioavailable?

Later published research identified lack of oral bioavailability as an important pharmacokinetic limitation of SLU-PP-332.

That limitation contributed to medicinal-chemistry research into chemically distinct pan-ERR agonists with different pharmacokinetic properties, including SLU-PP-915.

SLU-PP-915 subsequently demonstrated biological activity following oral administration in mouse research, creating an important experimental distinction between the two compounds.

Research Deep Dive

SLU-PP-332 vs SLU-PP-915

Compare ERR pharmacology, chemistry, oral activity, mitochondrial research and published preclinical evidence.

COMPARE COMPOUNDS →

SLU-PP-332 Metabolism Research

Analytical research published in 2026 further characterized the in-vitro metabolism of SLU-PP-332 using liver-derived experimental systems and high-resolution mass-spectrometry techniques.

The investigators reported nine SLU-PP-332 metabolites in the experimental systems studied, including six Phase-I metabolites and three Phase-II conjugates.

These findings contribute to analytical characterization and metabolite identification. In-vitro metabolism studies should not be interpreted as establishing human pharmacokinetics or clinical safety.

SLU-PP-332 Research FAQ

What is SLU-PP-332?

SLU-PP-332 is an experimental synthetic small molecule studied as an agonist of ERRα, ERRβ and ERRγ.

Is SLU-PP-332 a peptide?

No. SLU-PP-332 is a synthetic small molecule rather than a peptide chain.

What receptors does SLU-PP-332 target?

Published experimental research characterizes SLU-PP-332 as a pan-estrogen-related receptor agonist with activity across ERRα, ERRβ and ERRγ.

Is SLU-PP-332 a PGC-1α activator?

Its more precise pharmacological classification is a pan-ERR agonist. PGC-1 family coactivators are relevant to the broader transcriptional networks surrounding ERR signaling.

Why is SLU-PP-332 called an exercise mimetic?

Preclinical research has examined whether pharmacological ERR activation can reproduce selected molecular responses associated with aerobic exercise. The term describes a research concept and does not establish substitution for exercise in humans.

Is SLU-PP-332 orally bioavailable?

Published research has identified lack of oral bioavailability as a limitation of SLU-PP-332.

Has SLU-PP-332 demonstrated human clinical efficacy?

The research discussed here is preclinical. Laboratory and animal findings do not establish human clinical efficacy, dosing or safety.

Published SLU-PP-332 Research

  1. Billon C, et al. (2023). Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity. ACS Chemical Biology. PubMed →
  2. Hampton CS, et al. (2023). Medicinal-chemistry research involving potent pan-ERR agonists and the subsequent development of SLU-PP-915. PubMed Central →
  3. Billon C, et al. (2026). An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity. PubMed →
  4. Möller GM, et al. (2026). In Vitro Metabolism and Analytical Characterization of SLU-PP-332 and SLU-PP-915: Novel Pan-ERR Agonists With Doping Potential. Rapid Communications in Mass Spectrometry. PubMed →
Research Use Only: SLU-PP-332 is an experimental research compound. This material and the information presented here are intended for laboratory research and scientific-reference purposes only. Published laboratory and animal findings do not establish human dosing, efficacy or safety. Not for human consumption.

Research specifications

Chemical structure2D chemical structure reference for SLU-PP-332
View verified structure source
Scientific composition
Small molecule; peptide sequence not applicable.
Non-peptide molecules do not have an amino acid sequence.
PubChem CID5338394
ApplicationEstrogen-related receptor signaling research
Research targetsERR family
Compound classExperimental small molecule
Also known asSLU-PP-332
Sequence / chemistry notesSmall molecule; peptide sequence not applicable.
Molecular formulaC18H14N2O2
Molecular weight290.3 g/mol
Purity specification≥99% (product specification; batch COA separately)
FormLyophilized powder
StorageStore at −20°C; confirm product-specific handling